Endocrinology

Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

The pooled analysis of BROOKLYN and BROADWAY data outline obicetrapib’s impact on HbA1c reduction and a trend toward lower new-onset diabetes risk.

Michos discusses framing obesity as hyperandrogenism, with reductions in estrogen production contributing to higher visceral adiposity.

Pagidipati describes barriers to implementing guideline-directed medical therapy in patients with cardiometabolic diseases and steps needed to overcome them.

Khan’s presentation indicates that combination screening is the optimal method of identifying heart failure risk while minimizing the percentage of cases missed.

Hosts break down data from the CONFIDENCE trial on the safety and efficacy of finerenone plus empagliflozin in patients with T2D and CKD.

Semaglutide’s reduction in systolic blood pressure could indicate more potential for cardiovascular protection than simply its well-known glycemic benefits.

New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea and type 2 diabetes.

Get an overview of the top stories from May 2025 in endocrinology in our monthly recap!

Hosts discuss a consensus repot from the ADA focused on screening and early interview of MASLD in people with diabetes.

Hosts breakdown diabetes technology updates from May 2025 and Breakthrough T1D's push for improved screening.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and new treatment guidelines, in this week's essential news roundup.

The FDA approves hydrocortisone oral solution for pediatric adrenal insufficiency, enhancing dosing accuracy and ease for young patients and caregivers.

In this episode, hosts explore technosphere inhaled insulin (Afrezza) in comparison to standard diabetes therapies in the INHALE-3 trial.

Researchers uncover a mechanism of insulin resistance in obese adolescents, paving the way for potential interventions to prevent type 2 diabetes.

Hosts break down their biggest takeaways and detail their favorite sessions from the AACE 2025 annual meeting.

In this episode, hosts explore real-world data on Beta Bionics' iLet automated insulin delivery system for diabetes management.

Stay updated with the latest healthcare breakthroughs, including weight loss treatments, pediatric therapies, and FDA approvals shaping the future of medicine.

Adult-onset T1D significantly raises cardiovascular disease and mortality risks, highlighting the need for improved management and prevention strategies.

Hosts explore Luna Diabetes automated insulin delivery system, designed to enhance sleep and improve glucose control for people with diabetes who use pens.

Crinecerfont significantly reduces glucocorticoid use in pediatric CAH while improving hormone levels, enhancing long-term patient outcomes.

Discover the latest findings on tirzepatide vs semaglutide for obesity treatment, highlighting significant weight loss results & clinical insights.

New data reveal tirzepatide significantly outperforms semaglutide in weight loss.

In this episode, hosts explore updates on continuous glucose monitoring (CGM) systems from April 2025.